Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, with a particular emphasis on hereditary angioedema (HAE), a disorder characterized by recurrent swelling attacks. Their project pipeline includes novel, small-molecule bradykinin B2 receptor antagonists, designed to provide rapid and reliable relief for HAE sufferers. Pharvaris aims to advance the treatment landscape of HAE by harnessing cutting-edge technology and drug development strategies, striving to improve patient outcomes and quality of life. Their objectives are centered on pushing the boundaries of scientific research to deliver breakthrough solutions that address unmet medical needs within the rare disease community.